Category Archives: Pharmaceuticals

Trump tweet on drug prices sinks pharma shares; what’s next, doctors’ wages? Not.

Steve’s Take: President Trump’s morning ritual continues to enthrall millions, but occasionally causes Wall Street analysts covering the pharma industry to reach for their bottle of Maalox. After House Republicans… Read more »

Marathon’s defense of pricey orphan drug getting spotlight in Congress; running a marathon is far easier, and a lot cheaper

Steve’s Take: Marathon Pharmaceuticals LLC (Northbrook IL) caught my attention last month at the inception of an outcry when the company first announced the $89,000 price tag for its newly… Read more »

IPO Alert: Actelion founders launch startup on $1.5 billion J&J payday: call your broker, soon

Steve’s Take: If ever there was a “story” biotech IPO worth grabbing even a tiny piece of, this is it. First, the story: Two decades ago Jean-Paul and Martine Clozel… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Express Scripts says prescription drug spending slowed in 2016; but compared to what, a speeding train?

The News: According to a recent report released by Express Scripts Holding Co. (St. Louis MO), the average list price of the most commonly used branded drugs in the US… Read more »

Trump and pharma execs make nice; what, Sen. Sanders too?

The News: Last week (January 30, 2017), President Trump promised some of the nation’s top drug-company executives in a meeting at the White House that he would shrink Food and… Read more »

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?

News: Pfizer Inc.’s (New York City) key pneumococcal vaccine, Prevnar, whose sales soared through 2015, stumbled in fourth-quarter results (pdf) released last week. The blockbuster inoculation fell significantly short of Street… Read more »

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

Bristol Myers cuts guidance on cancer drug issues; shareholders scanning skies for vultures with deep pockets

The News: Bristol-Myers Squibb Co. (New York City) cut its earnings guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks… Read more »

Bristol-Myers plunges, Merck buoyed on cancer-drug news; is it still dash for cash, or race to nowhere?

The News: Bristol-Myers Squibb Co. (New York City) won’t seek accelerated approval of its immunotherapy drug Opdivo for lung cancer, confirming that Merck & Co. (Kenilworth NJ) will have a huge head start… Read more »